Bausch & Lomb’s Crystalens accommodating intraocular lens (IOL) was first approved by the FDA in November 2003. The Crystalens HD is said to be the fourth generation of the only FDA approved accommodating lens.
A total of 125 primary eyes were implanted with the Crystalens HD in patients who had a visually significant cataract, less than one diopter of corneal astigmatism, and the potential for best corrected visual acuity of 20/25 or better in both eyes. Of these patients, 80% reported vision at J2 or better at four months.
According to the company, the surface of the Crystalens HD has been shaped to enhance the depth of focus with a proprietary optical modification. The enhanced optic provides an increased depth of focus which is designed to improve near vision without compromising intermediate or distance vision.
Michael Judy, chief marketing officer OF Bausch & Lomb Surgical, said: “With these results, where patients reported getting one more line of near vision, we are coming ever closer to meeting the desired need for an optic that does provide truly good near vision without compromising the quality of vision at intermediate or distance.”